Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
27 authors.
Manu PrasadHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7690-3511
Alex T ChengHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0003-4460-9045
Marcel MayerHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9963-1109
Louis JansenHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-0332-1099
Elizabeth KohHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2049-1746
Zaineb NadeemHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0003-2190-9301
Gopika Sivan PillaiHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0001-5900-0748
Joris VosHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8318-5455
Fengshen KuoHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-1797-2896
Karena ZhaoHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3867-7474
Hannah J SfreddoHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-7169-0673
Andrew LeeHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2885-6316
Siqi ChenHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-9670-3805
Jennifer SchlossHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-6739-0902
Xinzhu DengHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0008-7709-3483
Swati JainHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8625-8218
Daniel MuldoonDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7936-4365
Chaitanya BandlamudiDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-1108-4919
Jens Peter KlussmannDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University Hospital Cologne, Cologne, Germany.ORCID 0000-0002-8223-7954
Thomas J OwHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9389-2332
Alan L HoDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6885-3742
Nancy Y LeeDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3044-9522
Nadeem RiazDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9873-5862
Richard J WongHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-6259-7314
Ian GanlyHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7636-5426
Nora KatabiDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-2974-3046
Luc G T MorrisHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-4417-2280
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
Clinical and Translational Science Center, Weill Cornell Medicine (CTSC) UL1TR002384Cycle for SurvivalGeoffrey Beene Cancer Research CenterNCATS NIH HHS UL1 TR002384NCI NIH HHS P30 CA008748U.S. Department of Defense (DOD) CA210784
6 · The paper itself
Abstract
purposeRecurrent and metastatic human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (R/M HPV+ HNSCC) remains largely incurable, with genetic drivers incompletely defined. We profiled the genetic landscape of R/M HPV+ HNSCC and functionally characterized genetic alterations strongly enriched in this cancer type. EXPERIMENTAL
designWe identified genetic alterations uniquely enriched in 159 R/M HPV+ tumors. High-priority alterations were functionally modeled, examining proliferation, clonogenicity, migration/invasion, apoptosis, therapy response, in vivo growth, metastasis, and immune contexture.
resultsCompared with HPV+ primary tumors, R/M HPV+ tumors were enriched for TP53 mutations (prespecified FDR threshold met; OR, 6.23; P = 0.02) and were associated with poorer survival. Within R/M disease, cylindromatosis lysine 63 deubiquitinase (CYLD) alterations were specific to HPV+ tumors (21% vs. 0% in HPV-). TP53 mutations were predominantly clonal and associated with whole-genome duplication. Expression of TP53 gain-of-function (GOF) mutants (R175H, G245C, R273C) in HPV+ HNSCC cells increased clonogenic survival, migration/invasion, lung metastatic burden in vivo, and cisplatin IC50, without altering radiation sensitivity. CYLD knockdown accelerated cellular growth yet increased radiosensitivity. Transcriptomic analyses linked CYLD loss to NF-κB/TNFα pathway activation, a T cell-inflamed microenvironment, and checkpoint upregulation.
conclusionsR/M HPV+ HNSCC is genomically and functionally shaped by two axes with therapeutic implications: TP53 GOF mutations promote metastatic phenotypes and cisplatin resistance, whereas CYLD loss defines an HPV-specific subset with enhanced radiation sensitivity and immune activation. These data support using TP53 and CYLD as predictive biomarkers to guide investigation into precision strategies for systemic therapy choices, p53-targeted/Wee1 strategies, and radiotherapy-immunotherapy combinations in high-risk or R/M HPV+ HNSCC.
Indexed as
Deubiquitinating Enzyme CYLDHead and Neck NeoplasmsNeoplasm Recurrence, LocalPapillomavirus InfectionsSquamous Cell Carcinoma of Head and NeckTumor Suppressor Protein p53AnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticGenomicsHuman Papillomavirus VirusesHumansMiceMutationCYLD protein, humanDeubiquitinating Enzyme CYLDTP53 protein, humanTumor Suppressor Protein p53
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Genomic Enrichment and Functional Impact of TP53 and CYLD Alterations in Recurrent and Metastatic HPV-Associated Head and Neck Cancer. · full record | OpenQuestion